2018, Number 1
<< Back Next >>
Med Cutan Iber Lat Am 2018; 46 (1)
Localized hyperhidrosis. Evaluation of the effectiveness, quality of life, safety and satisfaction after treatment with botulinum toxin
Resina E, Jones-Caballero M, Hernández-Núñez A, Pascual M, Daudén TE
Language: Spanish
References: 18
Page: 22-29
PDF size: 338.09 Kb.
ABSTRACT
Introduction: Localized hyperhidrosis is a chronic disease with an important negative impact on the patient’s quality of life.
Objectives: To valuate the short and long term effectiveness, quality of life, safety and satisfaction of the botulinum toxin (BTXA) therapy.
Material and methods: Observational, unicentric and retrospective study. Patients with moderate to severe localized hyperhidrosis unresponsive to conventional therapy were included. Treatment with subepidermal BTXA (75-100 U). Effectiveness was evaluated with an iodine-impregnated sheet and the Subjective Assessment of Sweating (SAS), and quality of life with the Skindex-29 questionnaire. Patients were scored at three weeks, three, six, nine and 12 months.
Results: 32 patients (24 women, eight men; 15 with palmar digital hyperhidrosis, eight axillary involvement, nine both). The best results were demonstrated at three weeks, with a mean improvement of the SAS and the area of palmar digital hyperhidrosis of 63.8% and 71.5%, respectively, and 73.9% and 91% for axillary hyperhidrosis (p ‹ 0.05). Significant improvement of the quality of life and a good safety profile were observed.
Conclusion: Botulinum toxin is an effective, rapid, easy to use and safe treatment for localized hyperhidrosis.
REFERENCES
Walling HW, Swick BL. Treatment options for hyperhidrosis. Am J Clin Dermatol. 2011; 12 (5): 285-295.
Weber A, Heger S, Sinkgraven R, Heckmann M, Elsner P, Rzany B. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br J Dermatol. 2005; 152 (2): 342-345.
Kouris A, Armyra K, Christodoulou C, Karimali P, Karypidis D, Kontochristopoulos G. Quality of life in patients with focal hyperhidrosis before and after treatment with botulinum toxin A. ISRN Dermatol. 2014; 2014: 308650.
Gross K, Schote A, Schneider K, Schulz A, Meyer J. Elevated social stress levels and depressive symptoms in primary hyperhidrosis. PLoS One. 2014; 9 (3): e92412.
Naumann M, Lowe NJ. Botulimun toxin type A in treatment of bilateral primary axillary hiperhidrosis: randomised, parallel group, double blind placebo controlled trial. BMJ. 2001; 323 (7313): 596-599.
Bushara KO, Park DM, Jones JC, Schutta HS. Botulinum toxin: a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol. 1996; 21 (4): 276-278.
Callejas MA, Grimalt R, Cladellas E. Actualización en hiperhidrosis. Actas Dermosifiliogr. 2010; 101 (2): 110-118.
Benson RA, Palin R, Holt PJ, Loftus I. Diagnosis and management of hyperhidrosis. BMJ. 2013; 347: f6800.
Jones-Caballero M, Penas P, García-Díez A, Badía X, Chren MM. The Spanish version of Skindex-29. Int J Dermatol. 2000; 39 (12): 907-912.
Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol. 2007; 56 (4): 604-611.
Campanati A, Sandroni L, Gesuita R, Giuliano A, Giuliodori K, Marconi B et al. Treatment of focal idiopathic hyperhidrosis with botulinum toxin type A: clinical predictive factors of relapse-free survival. J Eur Acad Dermatol Venereol. 2011; 25 (8): 917-921.
D’Espiro S, Macaluso L, Salvi M, Luci C, Mattozzi C. Safety and prolonged efficacy of botulin toxin A in primary hyperhidrosis. Clin Ther. 2014; 165 (6): e395-400.
Glaser D, Pariser D, Hebert A, Landells I, Somogyi C, Weng E et al. A prospective, nonrandomized, open-label study of the efficacy and safety of onabotulinumtoxina in adolescents with primary axillary hyperhidrosis. Pediatr Dermatol. 2015; 32 (5): 609-617.
Scamoni S, Valdatta L, Frigo C, Maggiulli F, Cherubino M. Treatment of primary axillary hyperhidrosis with botulinum toxin type A: our experience in 50 patients from 2007 to 2010. ISRN Dermatol. 2012; 2012: 702714.
Schnider P, Moraru E, Kittler H, Binder M, Kranz G, Voller B et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol. 2001;145: 289-293.
Prinsen C, Lindeboom R, Sprangers M, Legierse C, de Korte J. Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors. J Invest Dermatol. 2010; 130 (5): 1318-1322.
Lecouflet M, Leux C, Fenot M, Célerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients. J Am Acad Dermatol. 2013; 69 (6): 960-964.
Brehmer F, Lockmann A, Grönemeyer LL, Kretschmer L, Schön MP, Thoms KM. Repetitive injections of botulinum toxin A continuously increase the duration of efficacy in primary axillary hyperhidrosis: a retrospective analysis in 101 patients. J Dtsch Dermatol Ges. 2015; 13: 799-805.